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Abstract—Previous studies have shown that essential hypertension and obesity are both characterized by sympathetic
activation coupled with a baroreflex impairment. The present study was aimed at determining the effects of the
concomitant presence of the 2 above-mentioned conditions on sympathetic activity as well as on baroreflex
cardiovascular control. In 14 normotensive lean subjects (aged 33.562.2 years, body mass index 22.860.7 kg/m2
[mean6SEM]), 16 normotensive obese subjects (body mass index 37.261.3 kg/m2), 13 lean hypertensive subjects (body
mass index 24.060.8 kg/m2), and 16 obese hypertensive subjects (body mass index 37.561.3 kg/m2), all age-matched,
we measured beat-to-beat arterial blood pressure (by Finapres device), heart rate (HR, by ECG), and postganglionic
muscle sympathetic nerve activity (MSNA, by microneurography) at rest and during baroreceptor stimulation and
deactivation induced by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. Blood pressure
values were higher in lean hypertensive and obese hypertensive subjects than in normotensive lean and obese subjects.
MSNA was significantly (P,0.01) greater in obese normotensive subjects (49.163.0 bursts per 100 heart beats) and in
lean hypertensive subjects (44.563.3 bursts per 100 heart beats) than in lean normotensive control subjects (32.262.5
bursts per 100 heart beats); a further increase was detectable in individuals with the concomitant presence of obesity and
hypertension (62.163.4 bursts per 100 heart beats). Furthermore, whereas in lean hypertensive subjects, only baroreflex
control of HR was impaired, in obese normotensive subjects, both HR and MSNA baroreflex changes were attenuated,
with a further attenuation being observed in obese hypertensive patients. Thus, the association between obesity and
hypertension triggers a sympathetic activation and an impairment in baroreflex cardiovascular control that are greater
in magnitude than those found in either of the above-mentioned abnormal conditions alone. (Hypertension.
2000;36:538-542.)
Key Words: nervous system, sympathetic n nervous system, autonomic n baroreceptors
n hypertension, essential n obesity
Studies on the sympathoadrenal function in animal andhuman obesity have provided somewhat heterogeneous
results.1–5 However, several recent data have shown that
sympathetic activity, as directly assessed by regional norepi-
nephrine (NE) spillover or by microneurographic recording
of muscle sympathetic nerve activity (MSNA), is increased in
normotensive overweight subjects.6–9 A similar increase has
been shown to occur in lean individuals with essential
hypertension.10–14 However, whether this increase and the
one characterizing obesity are additive in an obese hyperten-
sive individual is not clear. In one study, the renal spillover of
NE was shown to be greater in obese hypertensive than in
obese normotensive subjects.15 However, this was not the
case in the cardiac and systemic circulation and in obese and
lean hypertensive individuals, who have been reported to
display similar NE spillover values in the kidney also.5,15
Furthermore, in another study, MSNA was not found to be
greater in normotensive and hypertensive obese subjects,
although obesity was defined only by a mild increase in body
weight.16
In the present study, we investigated whether sympathetic
activity is further increased in individuals with hypertension
and a marked increase in body weight compared with either
condition alone. Sympathetic activity was assessed by micro-
neurography and by plasma NE assay. The present study
included evaluation of the baroreceptor sympathetic reflex (a
major modulator of sympathetic drive), because this reflex
has been shown to be impaired in obesity but not in
hypertension.8,14
Methods
The study population consisted of 57 subjects of both genders (47
men, 10 women) and an age ranging from 22 to 50 years who were
classified as (1) normotensive if blood pressure (BP) was
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,140 mm Hg systolic or ,90 mm Hg diastolic or hypertensive if BP
was $140 mm Hg systolic or $90 mm Hg diastolic at repeated
sphygmomanometric measurements performed over 2 visits in the
outpatient clinics, (2) obese if body mass index (BMI, body weight
in kilograms divided by the square of the height in meters) was .27
kg/m2, and (3) lean if BMI was ,25 kg/m2. Exclusion criteria were
(1) secondary hypertension, (2) a family history of hypertension, (3)
an overt diabetes mellitus, (4) history, physical evidence, or labora-
tory evidence of congestive heart failure, coronary heart disease, or
other major cardiovascular disease, (5) history of major organ
damage (eg, serum creatinine .1.5 mg/dL, proteinuria, or echocar-
diographic left ventricular ejection fraction ,50%), and (6) history
of smoking and/or excessive alcohol consumption. All subjects were
studied as outpatients in the absence of antihypertensive or other
cardiovascular or metabolic drugs. In hypertensive subjects, antihy-
pertensive drugs were withdrawn at least 10 days before the study.
All subjects gave written informed consent to the study, whose
protocol was approved by the ethics committee of our institution.
Measurements
Supine BP was initially measured 3 times with a mercury sphygmo-
manometer; the first and fifth Korotkoff sounds identified systolic
and diastolic values, respectively, and a standard cuff and a tight cuff
(bladder, 1503330 mm and 1503360 mm) were used in lean and
obese subjects, respectively. In addition, arterial BP was monitored
by a finger photoplethysmographic device (Finapres 2300, Ohmeda),
capable of providing accurate and reproducible beat-to-beat systolic
and diastolic values.17 Heart rate (HR) was continuously monitored
by a cardiotachometer triggered by the R wave of an ECG lead.
Respiration rate was monitored by a strain-gauge pneumograph
positioned at the midchest level. Plasma NE was assayed the same
day of the study by high-performance liquid chromatography18 on a
blood sample withdrawn from a cannula placed in an antecubital vein
of the arm contralateral to that used for BP measurements.
MSNA was obtained from a microelectrode inserted in the right or
left peroneal nerve posterior to the fibular head, as previously
described.6–8,11–14 The microelectrode was made of tungsten and had
a diameter of 200 mm in the shaft, tapering to 1 to 5 mm at the
uninsulated tip. A reference electrode positioned subcutaneously 10
to 30 mm from the recording electrode served as the ground. The
nerve signal was amplified 370 000, fed through a band-pass filter
(700 to 2000 Hz), and integrated with a custom nerve traffic analysis
system (Bioengineering Department, University of Iowa, Iowa City).
Integrated nerve activity was monitored by a loudspeaker, displayed
on a storage oscilloscope (model 511A, Tektronix), and recorded
with BP, HR, and respiration rate on an ink polygraph (Gould 3800,
Gould Instruments). The muscle nature of the MSNA was assessed
according to the criteria outlined in previous studies,3–5,8–11 and the
recording was accepted only if the signal-to-noise ratio was .3.
Under baseline resting conditions, MSNA was quantified either as
number of bursts per minute or as number of bursts per 100 heart
beats. MSNA assessment by this quantification has been shown to be
highly reproducible, ie, to differ by only 3.8% when assessed on the
same tracing on 2 occasions by a single investigator.19
Baroreflex Evaluation
Baroreceptor modulation of MSNA and HR was assessed by the
technique on the basis of infusion of vasoactive drugs.8,14,19 Briefly,
phenylephrine was incrementally infused in an antecubital vein at
doses of 0.3, 0.6, and 0.9 mg/kg per minute, with each step being
maintained for 5 minutes. Nitroprusside was also incrementally
infused in an antecubital vein at doses on 0.4, 0.8, and 1.2 mg/kg per
minute, with each step being maintained for 5 minutes. In all
subjects, the drug initially infused was randomly selected, and the
end of the first infusion was separated from the beginning of the
second one by a recovery time of 45 minutes. Mean BP (diastolic BP
plus one third of pulse pressure), MSNA, and HR were averaged for
the 5 minutes before infusion and for the 5 minutes of each step
infusion. Baroreceptor modulation of MSNA and HR was estimated
by calculating (1) the change in the number of bursts per minute, (2)
the percent change in integrated activity (ie, mean burst amplitude
times bursts number over time), and (3) the change in HR in relation
to the change in mean BP induced by each dose of phenylephrine and
nitroprusside.
Protocol and Data Analysis
Obese and lean subjects came to the laboratory in the morning. They
were put in the supine position, and they were fitted with intravenous
cannulas, microelectrodes for MSNA recording, and other measuring
devices. Blood samples for assessment of plasma NE were then
taken, and BP was measured 3 times with the mercury sphygmoma-
nometer. After a 30-minute interval, BP, HR, respiration rate, and
MSNA were continuously measured during (1) an initial 10-minute
basal state, (2) the intravenous infusion of one vasoactive drug,
(3) a 45-minute recovery period followed by a second 10-minute
basal state, and (4) intravenous infusion of the second vasoactive
drug.
Data were collected in a quiet room at a constant temperature of
20°C to 21°C. Data were analyzed by a single investigator unaware
of the experimental design. Baseline BP, HR, and MSNA values
from individual subjects were averaged for each group and expressed
as mean6SEM. This procedure was also followed for the changes in
mean BP, MSNA, and HR induced by each dose of phenylephrine or
nitroprusside. Comparisons between data obtained in control, obese,
and lean subjects, with or without hypertension, were made by 2-way
ANOVA. The 2-tailed t test for unpaired observations was used to
locate between-group differences. The Bonferroni correction was
used to account for multiple comparisons. The relationships between
MSNA, BP, and BMI were assessed via multiple regression analysis.
A value of P,0.05 was considered statistically significant.
Results
Basal Values
As shown in the Table, the 4 groups of subjects were matched
for age. Body weight and BMI were similarly elevated in
normotensive and hypertensive obese groups compared with
normotensive and hypertensive lean groups to which they
were comparable. Systolic and diastolic BP were similarly
elevated in obese and lean hypertensive groups compared
with obese and lean normotensive groups to which they were
comparable. Respiration rate was superimposable in the 4
groups, whereas HR was significantly greater in the obese
hypertensive group than in the other 3 groups. Compared with
the lean normotensive control group, MSNA was markedly
greater in obese normotensive and lean hypertensive groups;
a further increase was observed in the group with the
association between obesity and hypertension. Plasma NE
showed a similar trend, although (unlike MSNA) the
between-group differences were not always statistically sig-
nificant. In the multiple regression analysis, MSNA values
were related to BMI (r50.72, P,0.001) and to mean BP
(r50.54, P,0.01).
Baroreflex Responses
The Figure shows that in all groups the stepwise increase in
mean BP induced by phenylephrine caused a progressive
bradycardia and reduction in MSNA, whereas the stepwise
decrease in mean BP induced by nitroprusside had opposite
effects. Compared with lean normotensive control subjects,
the reflex HR responses were less in the obese normotensive
and lean hypertensive subjects; a further reduction was
observed in obese hypertensive subjects. The reflex sympa-
thetic responses were preserved in lean hypertensive subjects,
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but they were reduced in obese normotensive subjects and
more reduced in obese hypertensive subjects.
Discussion
Confirming previous findings of our group and others,7–9,11–14
the present study determined that MSNA was greater in obese
normotensive and lean hypertensive subjects than in lean
normotensive control subjects. However, the new finding of
the present study is that in patients in whom hypertension was
associated with obesity, MSNA showed a further increase,
which was so marked as to make the increase caused by only
obesity and only hypertension additive. Thus, an additional
sympathetic hyperactivity is to be expected when dealing
with an increase in body weight accompanied by a BP
elevation.
The present study also provides data on the mechanisms
that may be responsible for the additive stimulatory effects of
obesity and hypertension on MSNA. Confirming previous
Baseline Demographic, Anthropometric, Hemodynamic, Microneurographic, and
Humoral Data for Lean Normotensive, Normotensive Obese, Lean Hypertensive,
and Obese Hypertensive Subjects
Variable
Control
Subjects
(n514)
Obese
Subjects
(n516)
Hypertensive
Subjects
(n513)
Obese
Hypertensive
Subjects
(n514)
Age, y 33.562.2 32.962.4 38.561.8 38.862.3
Gender, M/F 11/3 13/3 11/2 12/2
Body weight, kg 77.362.1 108.262.9*† 79.061.7 109.463.1*†
BMI, kg/m2 22.860.7 37.261.3*† 24.060.8 37.561.3*†
Sphygmo BP, mm Hg
Systolic 127.362.5 130.563.0 154.263.0*§ 156.263.3*§
Diastolic 75.562.0 76.162.1 97.163.1*§ 98.062.8*§
Finger BP, mm Hg
Systolic 124.462.1 128.062.7 150.462.4*§ 153.463.1*§
Diastolic 74.161.7 73.361.9 95.662.7*§ 96.762.6*§
Respiration rate,
breaths/min
21.260.8 22.061.0 21.860.9 22.261.1
Heart rate, bpm 69.962.0 69.262.4 71.562.1 80.162.4‡\¶
MSNA, bursts/min 21.961.2 34.361.8* 31.862.7* 49.962.9*\¶
MSNA, bursts/100
heart beats
32.262.5 49.163.0* 44.563.3* 62.163.4*†¶
NE, nmol/L 1.0860.12 1.5960.20‡ 1.3260.21 2.0860.23‡
Values are mean 6SEM. Sphygmo BP indicates sphygmomanometric BP (average of 3
measurements).
*P ,0.01 and ‡P ,0.05 vs control subjects; †P and \P ,0.05 vs hypertensive subjects; and
§P,0.01 and \P,0.05 vs obese subjects.
Plots showing changes in HR (DHR), expressed as beats per minute (b/min), and MSNA (DMSNA), expressed as bursts per minute
(bursts/min), and percent integrated activity (%i.a.), accompanying stepwise increases and reductions in mean BP (DMBP), induced by
intravenous infusion of phenylephrine and nitroprusside in lean normotensive control subjects (E), in lean hypertensive subjects (F), in
obese normotensive subjects (), and in obese hypertensive subjects (). Data are expressed as mean6SEM. *P,0.05 and **P,0.01
between groups.
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findings,14,20 we found the arterial baroreflex to show a
substantial loss of HR but not of MSNA modulation. How-
ever, compared with the control value, the baroreflex-
sympathetic modulation was clearly impaired in obese nor-
motensive patients and more so in obese hypertensive
patients. Therefore, it can be concluded that when obesity and
hypertension are present in the same patient, there is a
particularly striking impairment of a major mechanism re-
straining MSNA and that this may be a factor responsible for
the additional sympathetic hyperactivity that characterizes
this condition. Other factors, of course, might participate as
well. When obesity is associated with hypertension, for
example, there can be a more pronounced cardiac hypertro-
phy, which leads to a greater impairment of another reflex
that restrains MSNA, ie, the cardiopulmonary reflex.21 There
can also be a greater reduction of insulin sensitivity, a greater
increase in plasma renin activity, and a greater increase in
leptin and endothelin secretion that may all have a direct
sympathostimulating effect.22–25 Finally, there may be a
greater ischemic involvement of the chemoreceptors, trig-
gered by greater anatomic alterations of the arteries that
perfuse the carotid and aortic bodies, which may lead to a
reflex sympathostimulation greater than that ascribed to the
chemoreflex in hypertension and obesity alone.26–28 The
greater chemoreflex involvement may depend on a greater
prevalence of sleep apnea (a condition in which sympathetic
hyperactivity has been linked to chemoreceptor stimulation29
), because sleep apnea has been shown to more frequently
accompany hypertension than normotension and to be more
frequent in obese than in lean hypertensive patients.30
Several other findings of the present study deserve to be
discussed. First, our results do not agree with those of
Gudbjornsdottir et al,16 who did not find a significant differ-
ence in the degree of sympathetic activation between normo-
tensive and hypertensive obese subjects. However, it should
be emphasized that the subjects studied by Gudbjornsdottir et
al had an elevation in BP that was similar but an elevation in
body weight that was much less than that displayed by our
subjects. This may have been responsible for the negative
findings they obtained, because in previous studies as well as
in the present one, MSNA has been shown to be closely
related to both body weight and BP.7–8,11–14 This implies that
when one of the latter 2 variables is only modestly increased,
an interaction with the other one can be less easily detected.
Second, the present study does not clarify the mechanisms
responsible for the complex and diversified alterations of the
baroreflex seen in obesity and hypertension alone and com-
bined. In previous studies,14,31 however, we have argued that
in hypertension a greater impairment of HR versus peripheral
sympathetic influences of the baroreflex may depend on
central factors affecting the vagal more than the sympathetic
drive, as is the case for the defense-like reaction.32 This may
not be the case in obesity, in which a greater and more diffuse
baroreflex impairment may be caused by (1) a reduction in
arterial distensibility, ie, of the large-artery function, which
determines the activity of baroreceptors to respond to their
natural stimuli,33 and (2) a direct impairment in baroreceptor
function by the increased insulin levels secondary to insulin
resistance.34 A further reduction in arterial distensibility and
increase in insulin levels when obesity and hypertension are
combined may finally be responsible for the fact that in these
conditions the baroreflex is further impaired, with no more
sparing of its sympathetic component. Third, the technique
that we used allows only MSNA to be quantified, which
means that the present study cannot make any determinations
for an additive sympathostimulating effect of obesity and
hypertension in other vascular districts. However, in obese
hypertensive patients, there was also a further marked in-
crease in plasma NE (which derives from secretion in
different organs and thus represents a more composite marker
of sympathetic activity35), suggesting that the additive sym-
pathostimulating effects of these 2 conditions were not
limited to muscle districts. In this context, it should be
emphasized that NE spillover from the kidney has been
reported to be greater in obese than in lean normotensive
subjects9 and that compared with obese normotensive indi-
viduals, its value has been found to be greater in hypertensive
individuals, regardless of the presence of a normal or in-
creased body weight.15 This suggests that hypertension or
obesity alone is accompanied by an increased renal sympa-
thetic drive and also that their effect on this vascular district
may not necessarily be additive. It should also be mentioned
that cardiac NE spillover has not been reported to be clearly
increased in obese normotensive or in hypertensive individ-
uals,9,15 suggesting no effect of the overweight state on
cardiac adrenergic drive. This is not incompatible with our
present finding that HR was slightly greater in obese hyper-
tensive subjects than in subjects with obesity or hypertension
alone, because absolute HR values are known to be largely
determined by vagal influences, which make them an inac-
curate marker of cardiac sympathetic influences.36
Our results have several clinical implications. For example,
given the direct effect of sympathetic activity on myocyte
volume and vascular smooth muscle cell replication,37 the
marked sympathetic activations seen in obesity and hyperten-
sion may favor structural alterations of the heart, such as left
ventricular hypertrophy, and vascular lesions, such as those
associated with atherosclerosis. Furthermore, this greater
activation may also be responsible, at least in part, for the
greater incidence of sudden death reported in obese hyper-
tensive patients.38 Finally, on the basis of our findings, it can
be suggested that in obese hypertensive patients, the use of
drugs that reduce centrally or peripherally sympathetic car-
diovascular influences is appropriate for achieving BP control
and for organ protection.
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